Vasconcelos, I. C. | Search bioRxiv

bioRxiv2025

Abnormal expression of splicing regulators RBFOX and NOVA is associated with aberrant splicing patterns at the Neurexin-3 gene in a monogenic autism spectrum disorder

Autism spectrum disorders are diseases characterized by a combination of cognitive, behavioral and neurological symptoms. A complex interplay between environmental factors and a multitude of genetic determinants, most of them composed of low-risk variants, impose difficulties in understanding the molecular and cellular underpinnings of these conditions. In some cases, autistic patients have been shown to display alterations in splicing patterns of several genes, but the extent to which this phenomenon is common in the context of these multifactorial disorders is unknown, nor is it known if monogenic cases of autism also display dysregulation of splicing. Moreover, very few studies have investigated the causal links between splicing alterations in specific genes and the phenotypic characteristics of the neural tissue in autism patients. In this study, we have focused on a monogenic type of autism caused by haploinsufficiency of the Transcription Factor 4 gene, known as Pitt-Hopkins Syndrome. We show that neurons and organoids derived from patients with this disease have altered expression of splicing regulators in the NOVA and RBFOX families, accompanied by aberrant splicing patterns in a substantial number of genes involved in neural tissue development and synapse organization. We focused on a gene encoding a member of the Neurexin Family, the splicing of which normally leads to the production of transcript variants coding for both transmembrane and secreted protein isoforms. In Pitt-Hopkins Syndrome neurons, we detected an aberrant splicing pattern that results in lower expression of the secreted isoform and its corresponding transcript, a phenomenon that may explain why the neural tissue in these patients have decreased electrical activity through impaired synapse organization. Our data shed light on the role splicing regulation plays in a monogenic type of autism.

neuroscience↗

bioRxiv2018

A freeze-and-thaw induced-fragment of the microtubule-associated protein Tau in rat brain extracts: implications for the study of neurodegenerative diseases

Tau is a microtubule-associated protein responsible for controlling the stabilization of microtubules in neurons. Tau function is regulated by phosphorylation. However, in some neurological diseases Tau becomes aberrantly hyperphosphorylated, which contributes to the pathogenesis of neurological diseases, known as tauopathies. Western blotting (WB) has been widely employed to determine Tau levels in neurological disease models. However, Tau quantification by WB should be interpreted with care, as this approach has been recognized as prone to produce artifactual results if not properly performed. In this study, our goal was to evaluate the influence of a freeze-and-thaw cycle, a common procedure preceding WB, to the integrity of Tau in brain homogenates from rats, 3xTg-AD mice and human samples. Homogenates were prepared in ice-cold RIPA buffer supplemented with protease/phosphatase inhibitors. Immediately after centrifugation, an aliquot of the extracts was analyzed via WB to quantify total and phosphorylated Tau levels. The remaining aliquots were stored for at least 2 weeks at either -20{degrees}C or -80{degrees}C and then subjected to WB. Extracts from rodent brains submitted to freeze-and-thaw presented a ~25 kDa fragment immunoreactive to anti-Tau antibodies. An in-gel digestion followed by mass spectrometry analysis in excised bands revealed this ~25 kDa species corresponds to a Tau fragment. Freeze-and-thaw-induced Tau proteolysis was detected even when extracts were stored at -80{degrees}C. This phenomenon was not observed in human samples at any storage condition tested. Based on these findings, we strongly recommend the use of fresh extracts of brain samples in molecular analysis of Tau levels in rodents.

biochemistry↗